



**Aytu**  
BIOPHARMA

**NASDAQ: AYTU**

**OCTOBER 2024 / 2024 年10月**



# FORWARD LOOKING STATEMENTS / 前瞻性聲明

This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. All statements other than statements of historical facts contained in this presentation, are forward-looking statements. Forward-looking statements are generally written in the future tense and/or are preceded by words such as "may," "will," "should," "forecast," "could," "expect," "suggest," "believe," "estimate," "continue," "anticipate," "intend," "plan," or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. All statements other than statements of historical facts contained in this presentation, are forward-looking statements. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others, risks associated with: the Company's plans relating to the Company's overall financial and operational performance, the Company's commercial performance, regulatory status, reimbursement status, and other factors affecting their commercial uptake, clinical development and commercialization of the Company's current and future development assets, the anticipated start dates, durations and completion dates, as well as the potential future results of the Company's ongoing and future clinical trials, the anticipated designs of the Company's future clinical trials, and the anticipated future regulatory submissions, potential adverse changes to the Company's financial position or business plans, the results of operations, strategy and plans, changes in capital markets and the ability of the Company to finance operations in the manner expected, risks relating to gaining market acceptance of the Company's products, risks related to the ongoing COVID-19 pandemic and its impact on the Company's operations, the Company's ability to effectively integrate operations and manage integration costs following the Company's recent acquisitions, the Company's partners performing their required activities, the Company's anticipated future cash position, regulatory and compliance challenges and future events under current and potential future collaboration. Additional risks are described in "Risk Factors" in Part I, Item 1A of Aytu BioPharma's most recent Annual Report on Form 10-K and in the other reports and documents it files with the United States Securities and Exchange Commission.

# SUCCESSFUL MULTI-YEAR STRATEGIC REALIGNMENT TO FOCUS COMPANY ON PROFITABLE PRESCRIPTION DRUG BUSINESS COMPLETED


## 成功完成多年戰略調整，使公司能夠專注於盈利性處方藥業務

**\$44 million Adjusted EBITDA improvement over three-year period**

三年時間內調整後息稅折舊攤銷前利潤（EBITDA）增長了\$4400萬


### ADJUSTED EBITDA / 調整後息稅折舊攤銷前利潤


June 30 Fiscal Year-End  
截止6月30日財年結束





### KEY TRANSFORMATIVE EVENTS


重大變革事件

- 

March 2022 – Discontinuation of Non-Core, Low Margin Prescription Products / 2022年3月—停止非核心、利潤率低的處方產品
- 

October 2022 - Indefinite Suspension of Clinical Development Programs / 2022年10月—無限期中止臨床開發項目
- 

June 2024 – Paydown and Refinancing of Term Loan on Improved Terms / 2024年6月—以修改後的條款償還定期貸款並進行再融資
- 

June 2024 – Completed Outsource to Third-Party Contract Manufacturer / 2024年6月—完成外包給第三方合同制造商
- 

July 2024 – Completed Wind Down of Consumer Health Segment / 2024年7月—完成對消費者保健業務部門的縮減

# AYTU IS A WELL-POSITIONED SPECIALTY PHARMACEUTICAL PLATFORM

## Aytu是一個定位準確的專業制藥平臺

Leveraging the unique capabilities of the now streamlined organization to grow commercialized novel prescription therapeutics and drive cash flow and profitability.

利用已精簡組織機構的獨特能力，發展商業化的新型處方療法，並推動現金流和盈利能力。

### NOVEL PATENT-PROTECTED PRESCRIPTION PRODUCTS

受專利保護的新型處方產品



#### Effective, Extended-Release ADHD Treatments

有效的緩釋多動症治療方法

- Extended-release orally disintegrating tablets for the treatment of attention deficit hyperactivity disorder (ADHD) / 用於治療注意力缺陷多動障礙 (ADHD) 的緩釋口腔崩解片



#### Complementary Pediatric Product Lines

兒科產品系列補充

- Extended-release antihistamine & multi-vitamin + fluoride supplement line containing novel L-methylfolate suitable for pediatric population / 緩釋抗組胺劑和多種維生素+氟化物補充劑系列，含有適合兒童的新型L-甲基葉酸



#### Aytu RxConnect® Patient Access Program

Aytu RxConnect®患者加入計劃

- Patient support program operates through a network of approximately 1,000 pharmacies to offer affordable, predictable co-pays / 患者支持計劃通過近1000家藥房網絡運作，提供可負擔、可預測的共同付費



#### Commercial Sales Infrastructure

商業銷售基礎設施

- Efficient, leverageable commercial infrastructure for Rx Portfolio through 40 internal sales reps / 通過40名內部銷售代表，為藥物組合提供高效、可利用的商業基礎設施

### PRODUCT LICENSING OPPORTUNITIES

產品許可機會



#### Global Footprint Expansion Through Out-Licensing

通過對外授權擴大全球業務範圍

- International expansion via out-licensing with current agreements in place for Canada and Israel with more expected in the future / 通過對外授權進行國際擴張，目前已與加拿大和以色列簽訂了協議，預計未來還會簽訂更多協議



#### New Product In-Licensing/Acquisition

新產品內部許可/收購

- Leverage experience of a portfolio built through efficient M&A to add accretive, novel prescription products to commercial portfolio / 利用通過高效並購建立的產品組合的經驗，為商業產品組合增加具有增效作用的新型處方產品



#### Operating Expense Reductions

減少運營開支

- Company has cut nearly \$40 million in annualized costs from operating expenses over the past two years / 在過去兩年中，公司從年化運營支出中削減了近\$4000萬的成本



#### Manufacturing Outsourcing

制造外包

- Completed outsource of ADHD manufacturing to CMO; helps drive improvement in gross margins / 完成了將ADHD生產外包給CMO的工作；有助於提高毛利率



# COMPELLING VALUATION / 令人信服的估值

Today, Aytu is trading at 1.3x EV/EBITDA and 0.21x EV/Sales on the go forward Rx business  
Aytu今天的交易價格是其未來處方藥業務企業價值/EBITDA的1.3倍，是企業價值/銷售額的0.21倍

FY 24 RX REVENUE / 2024財年處方藥收入

\$65.2 M / \$6520萬

FY 24 RX GROSS MARGINS / 2024財年處方藥毛利率

75%

FY 24 ADHD REVENUE GROWTH  
2024財年多動症產品收入增長

+23%

FY 24 RX ADJUSTED EBITDA  
2024財年處方藥業務調整後EBITDA

\$10.8 M / \$1080萬

CASH (JUNE 2024) / 現金 (2024年6月)

\$20.0 M / \$2000萬

DEBT (JUNE 2024) / 債務 (2024年6月) <sup>1</sup>

\$15.1

PRO FORMA EV/SALES / 預估企業價值/銷售額 <sup>2,3</sup>

0.21 x

PRO FORMA EV/EBITDA / 預估企業價值/EBITDA <sup>2,3</sup>

1.3 X

<sup>1</sup> Inclusive of revolving line of credit; maturity June 2028 / 包括循環信貸額度；2028年6月到期

<sup>2</sup> Enterprise value of \$13.6 M based on 5.972M shares outstanding @ \$2.27 per share on October 9, 2024 / 按2024年10月9日流通股597.2萬股，每股\$2.27計算，企業價值為\$1360萬

<sup>3</sup> Pro Forma reflects valuation of go forward Rx business only / 預估僅反映處方藥業務的未來估值

# NOVEL, PATENT-PROTECTED REVENUE GENERATING PRESCRIPTION PORTFOLIO

## 新穎、受專利保護的創收處方產品組合

Differentiated Rx brands focused on ADHD and Pediatrics  
專注於多動症和兒科的差異化處方藥品牌

### IP-PROTECTED ADHD BRANDS 受知識產權保護的多動症品牌

**Adzenys XR-ODT**<sup>®</sup>  
Extended-Release Orally Disintegrating Tablets  
(amphetamine) 3.1 mg, 6.3 mg, 9.4 mg, 12.5 mg, 15.7 mg, 18.8 mg

- **First & only extended-release ODT amphetamine / 首款也是唯一一款緩釋ODT苯丙胺藥物**
- **Only branded amphetamine that is FDA-approved as bioequivalent to Adderall XR / 唯一經FDA批准與Adderall XR具有生物等效性的苯丙胺品牌**

**Cotempla XR-ODT**<sup>®</sup>  
Extended-Release Orally Disintegrating Tablets  
(methylphenidate) 8.6 mg, 17.3 mg, 25.9 mg

- **First & only extended-release ODT methylphenidate / 首款也是唯一一款緩釋ODT哌醋甲酯**
- **Strong clinical data in patients 6-17 years old, demonstrated 61% symptom improvement @ 1 hour / 針對6-17歲患者的大量臨床數據顯示，服用1小時後症狀改善率達 61%**

### IP-PROTECTED PEDIATRIC BRANDS 受知識產權保護的兒科品牌

**Karbinal ER**  
(carbinoxamine maleate) extended-release  
oral suspension | 4mg/5mL

- **Only FDA-approved, extended-release carbinoxamine liquid / 唯一獲得FDA批准的緩釋卡比沙明液體**
- **Broad indications for use, including as an adjunctive treatment for anaphylaxis / 使用適應症廣泛，包括對過敏性休克的輔助治療**

**Poly-Vi-Flor**<sup>®</sup>  
(chewable tablet/drops)

**Tri-Vi-Flor**<sup>®</sup>

- **First and only multi-vitamin + fluoride supplement containing novel L-methylfolate Arcofolin<sup>®</sup>**
- **首款也是唯一一款含有新型L-甲基葉酸Arcofolin<sup>®</sup>的複合維生素+氟化物補充劑**


# STRONG PRESCRIPTION GROWTH ACROSS ADHD PORTFOLIO

## 多動症產品組合處方量增長強勁


Since FY 2021, the total prescriptions written monthly for the Company's core ADHD product portfolio have increased significantly / 自2021財年以來，公司核心多動症產品組合的每月總處方量大幅增加

Pediatric product unit shipments have increased 131% from July 2024 to September 2024  
從2024年7月到2024年9月，兒科產品單位出貨量增長了131%


**ADHD Portfolio (TRxs)**  
多動症產品組合 (TRxs)



**Pediatric Portfolio (TRxs)**  
兒科產品組合 (TRxs)



**Combined (TRxs)**  
合併後 (TRxs)




# RX SEGMENT REVENUE / 處方藥業務收入

ADHD Portfolio (Adzenys XR-ODT® and Cotempla XR-ODT®) revenue increased 23% in fiscal 2024 to \$57.8 million versus \$46.9 million in fiscal 2023. / 多動症產品組合（Adzenys XR-ODT®和Cotempla XR-ODT®）的收入在2024財年增長了23%，達到\$5780萬，2023財年為\$4690萬。

The Company expects revenue growth across the Rx Segment in fiscal 2025.  
公司預計2025財年處方藥業務的收入將繼續增長。

## RX REVENUE BY PRODUCT CATEGORY 按產品類別劃分的處方藥業務收入






# AYTU RXCONNECT PATIENT ACCESS PROGRAM

## AYTU RXCONNECT患者加入計劃

*Aytu RxConnect is a proprietary, best-in-class patient access program, supported by an efficient commercial infrastructure, that enables affordable, predictable, hassle-free patient access to Aytu Rx products.*

**Aytu RxConnect**是一項專有的、一流的患者加入計劃，由高效的商業基礎設施提供支持，使患者能夠以可負擔、可預測、無障礙的方式使用**Aytu**的處方藥產品。

- **Developed in-house to drive patient adherence** and increased script pull-through of Aytu's Rx brands / 內部開發，促進患者堅持用藥，提高Aytu藥店品牌的處方藥銷量
- **~1,000 pharmacies nationwide** with 100% sales territory coverage; fully supported by in-house pharmacy support team / 全國約**1000**家藥店，100%的銷售區域覆蓋率；由內部藥店支持團隊提供全面支持
- Offers prescribers and patients **affordability, predictability and access** to Aytu brands for all commercially insured patients / 為處方醫生和患者提供可負擔、可預測的Aytu品牌產品，使所有商業保險患者都能獲得這些產品
- Reduces pharmacy call backs relating to payor access barriers (stock outs, prior authorizations, step edits, etc.) / 減少藥房因付款人訪問障礙（缺貨、事先授權、步驟編輯等）而導致的電話回訪
- **+85% of company scripts** driven through *Aytu RxConnect* network / 超過**85%**的公司藥方通過Aytu RxConnect網絡驅動



# AYTU RXCONNECT PATIENT ACCESS PROGRAM

## AYTU RXCONNECT患者加入計劃

The *Aytu RxConnect* platform delivers value for patients, prescribers, and Aytu / Aytu RxConnect 平臺為患者、處方醫生和 Aytu 帶來價值  
 >85% of Aytu's core brands are dispensed through *Aytu RxConnect* partner pharmacies / 超過85%的 Aytu 核心品牌通過 Aytu RxConnect 合作藥房配藥

### How *Aytu RxConnect* Delivers


### Value for Patients & Aytu: /

### *Aytu RxConnect* 如何為患者和

### Aytu 帶來價值:

- 30% Reduction in Patients' Out-of-Pocket Costs / 患者自付費用減少30%
- 109% Increase in Rx Refills / 處方藥補充量增加109%

% Core Products TRx through Aytu RxConnect Pharmacies  
 通過 Aytu RxConnect 藥房提供的核心產品 TRx 所占的百分比




# BROAD COMMERCIAL SALES INFRASTRUCTURE

## 廣泛的商業銷售基礎設施

Efficient, leverageable commercial infrastructure for Rx Portfolio through 40 internal commercial representatives allows for easily scalable product expansion opportunities  
通過40名內部商業代表，為處方藥組合提供高效、可利用的商業基礎設施，輕鬆實現產品擴展機會

- **Lean, direct sales force covers 59% of \$12B ADHD market / 精幹的直銷隊伍在\$120億的多動症藥物市場占據了59%的份額**
  - **Additional 37% of market covered by virtual sales initiatives / 線上銷售計劃再覆蓋37%的市場**
- **Sales force augmented by ~1,000 Aytu RxConnect pharmacy partners / 約1000個Aytu RxConnect藥房合作夥伴壯大了銷售力量**
- **Further support enabled through channel network partners, in-house staff, analytics platform, and selective direct-to-patient initiatives / 通過渠道網絡合作夥伴、內部員工、分析平臺和選擇性的直接面向患者的舉措，提供進一步支持**





# GLOBAL FOOTPRINT EXPANSION THROUGH OUT-LICENSING OF ADHD BRANDS

## 通過對外授權多動症藥物品牌擴大全球業務範圍

Ex-U.S. royalty revenue coming from ADHD brands in Canada & Israel with additional territories under discussion / 美國以外的特許權使用費收入來自加拿大和以色列的多動症品牌，其他地區的特許權使用費收入正在討論中

>\$1.5B in annual ADHD revenue across target territories / 考慮的目標地區多動症藥物年收入超過\$15億

### MEDOMIE PHARMA IN ISRAEL 以色列Medomie製藥公司



- ✓ In July 2023, we entered into an exclusive collaboration, distribution and supply agreement with Medomie to sell Adzenys and Cotelpla in Israel. / 2023年7月，我們與Medomie簽訂了一項獨家合作、分銷和供應協議，在以色列銷售Adzenys和Cotelpla。
- ✓ Medomie will be responsible for seeking local regulatory approvals and marketing authorizations for each product / Medomie將負責為每種產品尋求當地監管部門的批准和營銷授權

### LUPIN IN CANADA 加拿大LUPIN製藥公司



- ✓ In October 2024, we entered into an exclusive collaboration, distribution and supply agreement with Lupin Pharma Canada Ltd. to sell Adzenys and Cotelpla in Canada. / 2024年10月，我們與Lupin Pharma Canada Ltd.簽訂了一項獨家合作、分銷和供應協議，在加拿大銷售Adzenys和Cotelpla。
- ✓ Lupin will seek regulatory approvals and marketing authorizations for both Adzenys XR-ODT and Cotelpla XR-ODT in the >\$1B (CAD) ADHD market. / Lupin將為Adzenys XR-ODT和Cotelpla XR-ODT在超過\$10億加元的多動症市場尋求監管批准和營銷授權。

# DIVERSIFICATION & GROWTH THROUGH BUSINESS DEVELOPMENT

## 通過業務發展實現多樣化和增長

Leverage experience of a portfolio built through efficient M&A to add accretive, novel, branded prescription products to commercial portfolio

利用通過高效並購建立的產品組合經驗，為商業產品組合增加具有增值效應的新型品牌處方藥產品

### HISTORY OF SUCCESSFUL PRODUCT ACQUISITIONS 成功收購產品的歷史



### IN-LICENSE/ACQUISITION OF ESTABLISHED RX BRANDS 內部許可/收購成熟的處方藥品牌

✓ Launching in-licensed, mature ADHD brand in 2025 / 2025年推出獲得許可的成熟多動症品牌



### SEEKING BOLT-ON BRANDED RX PRODUCTS 尋求補強品牌的處方藥產品

- ✓ Leverage commercial infrastructure / 利用商業基礎設施
- ✓ Aytu RxConnect-aligned opportunities / 與Aytu RxConnect共進退的機會
- ✓ Accretive to earnings / 增加收益



# FINANCIALS

## 財務狀況



# SEGMENT REVENUE & ADJUSTED EBITDA

## 各部門收入與調整後的EBITDA


Wind down and divestiture of the Consumer Health Segment in July 2024 / 2024年7月逐漸關閉並剝離消費者保健業務部門

Indefinite suspension of clinical development programs began in October 2022 / 2022年10月開始無限期暫停臨床開發項目

Go forward business focused exclusively on Rx Business / 繼續專注於處方藥業務

### REVENUE BY SEGMENT / 按業務部門劃分的收入


June 30 Fiscal Year-End  
截止6月30日財年結束



Core Go-Forward Business  
核心未来业务

### ADJUSTED EBITDA BY SEGMENT 按業務部門劃分的調整後EBITDA

June 30 Fiscal Year-End截止6月30日財年結束



Core Go Forward Business  
核心未来业务

# SEGMENT GROSS MARGIN & OPEX

## 各部門毛利率和運營支出


Go forward business focused exclusively on Rx Segment / 未來業務重點完全放在處方藥業務上

Production outsourcing and volume increases have driven Rx segment gross margin improvement / 生產外包和銷量增長推動了處方藥部門毛利率的提高

Efficiencies expected due to additional operational consolidation / 預計將通過進一步的業務整合提高效率


### GROSS MARGIN BY SEGMENT / 按業務部門劃分的毛利率

June 30 Fiscal Year-End / 截止6月30日財年結束



### OPEX BY SEGMENT / 按業務部門劃分的運營支出<sup>1</sup>

June 30 Fiscal Year-End / 截止6月30日財年結束



<sup>1</sup> Excludes Impairment expense, Restructuring costs, Gain (loss) from derecognition of contingent consideration liability, and Amortization of intangible assets / 不包括減值支出、重組成本、終止確認或有對價負債的收益（損失）和無形資產攤銷

# BALANCE SHEET HIGHLIGHTS / 資產負債表亮點

Successfully refinanced previous term loan and extended revolving credit facility on more favorable terms to the Company in June 2024. / 2024年6月以更有利的條件成功地對之前的定期貸款進行了再融資，並延長了循環信貸額度期限。

Company received \$3.5 million of additional capital through the exercise of warrants in June 2024, a portion of which was used to pay down the term loan indebtedness. / 公司通過在2024年6月行使認股權證獲得了\$350萬的額外資金，其中一部分用於償還定期貸款債務。

(in thousands except shares outstanding) / (以千為單位，流通股數量除外)	6/30/2024
Cash and cash equivalents / 現金及現金等價物	\$20,006
Total current assets / 流動資產共計	\$61,891
Intangible assets, net / 無形資產淨值	\$52,453
Total assets / 資產總額	\$118,095
Total current liabilities / 流動負債共計	\$62,228
Borrowings include \$12,734 Term Note and \$2,395 o/s on Revolving Credit / 借款包括\$12,734的定期票據和\$2395未收回的循環信貸	\$15,129
Total liabilities / 負債總額	\$90,379
Total stockholders' equity / 股東權益總額	\$27,716
Shares Outstanding / 流通股數量	5,972,638
Fully Diluted Shares, Warrants and Equity Awards Outstanding / 完全稀釋後流通股、未行權的認股權證和股權獎勵 <sup>1</sup>	12,196,832

<sup>1</sup> Includes outstanding warrants (6,075,880), RSUs (1,775), employee equity awards (146,539) / 包括未行權的認股權證 (6,075,880份)、受限股票單位 (1775份)、員工股權獎勵 (146,539份)



# VALUE CREATION DRIVERS / 創造價值的驅動力

Strategic focus on cash flows and earnings, coupled with future growth opportunities that leverage of existing commercialization infrastructure, to drive value creation.

戰略重點是現金流和盈利，以及利用現有商業化基礎設施的未來增長機會，推動價值創造。

## STRONG BASE ESTABLISHED

### 建立了堅實的基礎

- ✓ Strategic realignment now complete having resulted in two consecutive years of companywide positive Adjusted EBITDA (\$9.2M in FY 2024 vs \$3.5M in FY 2023) / 戰略調整已完成，全公司調整後息稅折舊攤銷前利潤（EBITDA）連續兩年為正（2024財年為\$920萬，\$2023財年為\$350萬）
- ✓ Organic growth of core ADHD Portfolio in FY 2024 with expectations for net revenue growth across the Rx Segment in fiscal 2025 / 2024財年，核心多動症產品組合實現有機增長，預計2025財年，整個處方藥部門將實現淨收入增長
- ✓ Pediatric Portfolio demonstrating strong fiscal 2025 rebound; Product unit shipments have increased 115% from July 1, 2024 to September 25, 2024 / 兒科產品組合在2025財年出現強勁反彈；從2024年7月1日至2024年9月25日，產品單位出貨量增長了115%
- ✓ Strong cash position of \$20.0 M as of June 2024  
截至2024年6月，擁有\$2000萬的現金
- ✓ Improved balance sheet through successful refinancing of previous term loan and extension of revolving credit facility on more favorable terms. / 通過成功地對之前的定期貸款進行再融資，並以更優惠的條件延長循環信貸額度，改善了資產負債表。

## FUTURE GROWTH OPPORTUNITIES

### 未來的增長機會

- ✓ Diversification and growth through business development by leveraging strong commercial infrastructure (Aytu RxConnect + internal sales reps) / 利用強大的商業基礎設施（Aytu RxConnect + 內部銷售代表），通過業務開發實現多樣化和增長
- ✓ In-licensing/acquisition of new products aligned with commercial footprint and capabilities / 根據商業足跡和實力許可/收購新產品
- ✓ Global footprint expansion through ex-U.S. royalty revenue coming from ADHD brands, initially in Canada and Israel / 通過多動症品牌（最初在加拿大和以色列）在美國以外地區的特許權使用費收入，擴大在全球的業務範圍
- ✓ Further monetization of Consumer Health segment through revenue-based royalty payments on future sales of former Consumer Health business products / 通過向之前的消費者保健業務產品的未來銷售支付基於收入的特許權使用費，進一步實現消費者保健業務的貨幣化
- ✓ Expansion of coverage and commercial sales footprint through distribution partners / 通過分銷合作夥伴擴大業務覆蓋範圍和商業銷售版圖

# EXPERIENCED MANAGEMENT TEAM

## 經驗豐富的管理團隊



**Josh Disbrow**  
Chairman & Chief Executive Officer  
董事會主席兼首席執行官



**Mark Oki**  
Chief Financial Officer  
首席財務官



**Greg Pyszczymuka**  
Chief Commercial Officer  
首席商務官



**Margaret Cabano**  
Vice President of Operations  
運營副總裁



**Suzane Kennedy**  
Vice President of Regulatory Affairs  
and Quality Assurance  
監管事務與質量保證副總裁



**Jarrett Disbrow**  
Chief Business Officer  
首席業務官



**Ryan Selhorn**  
Executive Vice President of Finance  
and Business Optimization  
財務與業務優化執行副總裁





# APPENDIX

## 附錄



# ADJUSTED EBITDA RECONCILIATION

## 調整後息稅折舊攤銷前利潤（EBITDA）對賬

\$ in millions / \$百萬

	FY21	FY22	FY23	FY24
	Jun	Jun	Jun	Jun
<b>Adjusted EBITDA Reconciliation</b>				
Net income (Loss)	\$ (58.289)	\$ (110.173)	\$ (17.051)	\$ (15.844)
Interest expense-net	\$ 2.836	\$ 3.442	\$ 4.963	\$ 4.792
Income tax (expense) benefit	\$ 0.259	\$ (0.110)	\$ -	\$ 1.768
Depreciation & Amort.	\$ 7.688	\$ 9.378	\$ 7.387	\$ 7.457
Impairment of goodwill/intangibles	\$ 12.825	\$ 75.458	\$ 7.824	\$ 0.730
Stock-based compensation expense	\$ 3.574	\$ 5.247	\$ 6.045	\$ 2.914
Other Expense (Income), net	\$ (0.786)	\$ (2.580)	\$ (0.184)	\$ (0.568)
Loss (gain) from contingent considerations	\$ (4.459)	\$ (1.760)	\$ (0.969)	\$ -
Gain (Loss) on debt extinguishment	\$ 1.569	\$ (0.169)	\$ -	\$ 0.594
(Gain) Loss on Derivative Warrant Liability	\$ -	\$ (0.211)	\$ (4.793)	\$ 4.004
One time transactions	\$ -	\$ -	\$ 0.300	\$ 1.001
Restructuring Costs	\$ -	\$ -	\$ -	\$ 2.365
<b>Adjusted EBITDA from continuing operations</b>	<b>\$ (34.783)</b>	<b>\$ (21.478)</b>	<b>\$ 3.522</b>	<b>\$ 9.213</b>

# RX ADJUSTED EBITDA RECONCILIATION

## 處方藥業務調整後息稅折舊攤銷前利潤（EBITDA）對賬

\$ in millions / \$百萬

	FY21	FY22	FY23	FY24
	Jun	Jun	Jun	Jun
<b>Adjusted EBITDA Reconciliation</b>				
Net income (Loss)	\$ (46.518)	\$ (81.109)	\$ (4.694)	\$ (11.163)
Interest expense-net	\$ 2.605	\$ 3.310	\$ 4.908	\$ 4.757
Income tax (expense) benefit	\$ 0.259	\$ (0.110)	\$ -	\$ 1.768
Depreciation & Amort.	\$ 5.887	\$ 7.821	\$ 6.271	\$ 5.910
Impairment of goodwill/intangibles	\$ 12.825	\$ 64.649	\$ 2.730	\$ -
Stock-based compensation expense	\$ 3.138	\$ 4.674	\$ 5.699	\$ 2.374
Other Expense (Income), net	\$ (0.803)	\$ (2.583)	\$ (0.184)	\$ (0.568)
Loss (Gain) from contingent considerations	\$ (4.459)	\$ (1.760)	\$ (0.578)	\$ 4.004
Gain (Loss) on debt extinguishment	\$ 1.569	\$ (0.169)	\$ -	\$ 0.594
Gain on Derivative Warrant Liability	\$ -	\$ (0.211)	\$ (4.793)	\$ -
One time transactions	\$ -	\$ -	\$ 0.300	\$ 1.001
Restructuring Costs	\$ -	\$ -	\$ -	\$ 2.156
<b>Adjusted EBITDA from cont operations</b>	<b>\$ (25.497)</b>	<b>\$ (5.488)</b>	<b>\$ 9.659</b>	<b>\$ 10.833</b>

# CONSUMER HEALTH ADJUSTED EBITDA RECONCILIATION

## 消費者保健業務调整后息税折旧摊销前利润（EBITDA）对账

\$ in millions / \$百萬

	FY21	FY22	FY23	FY24
	Jun	Jun	Jun	Jun
<b>Adjusted EBITDA Reconciliation</b>				
Net income (Loss)	\$ (7.760)	\$ (17.465)	\$ (9.761)	\$ (3.698)
Interest expense-net	\$ 0.231	\$ 0.132	\$ 0.055	\$ 0.035
Income tax (expense) benefit	\$ -	\$ -	\$ -	\$ -
Depreciation & Amort.	\$ 1.801	\$ 1.557	\$ 1.116	\$ 1.547
Impairment of goodwill/intangibles	\$ -	\$ 10.809	\$ 5.094	\$ 0.730
Stock-based compensation expense	\$ 0.436	\$ 0.058	\$ 0.324	\$ 0.540
Other Expense (Income), net	\$ 0.017	\$ 0.003	\$ -	\$ -
Loss (gain) from contingent considerations	\$ -	\$ -	\$ (0.391)	\$ -
Gain (Loss) on debt extinguishment	\$ -	\$ -	\$ -	\$ -
Restructuring Costs	\$ -	\$ -	\$ -	\$ 0.209
<b>Adjusted EBITDA from cont operations</b>	<b>\$ (5.275)</b>	<b>\$ (4.906)</b>	<b>\$ (3.563)</b>	<b>\$ (0.637)</b>